Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HER2HEART-US: Carvedilol and Empagliflozin for Cardiotoxicity Prevention in HER2+ Breast Cancer
NCT06844669Phase 2Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Apr 2025
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of carvedilol, empagliflozin in Cardiotoxicity, sponsored by Washington University School of Medicine. Started Apr 2025; status: terminated.
02
Drugs
carvedilolempagliflozin
03
Conditions
Cardiotoxicity
Beyond the preview
Go deeper on NCT06844669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06844669.